Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Treasury Shares (2020 - 2025)

Adma Biologics' Treasury Shares history spans 1 years, with the latest figure at $32.1 million for Q4 2025.

  • For Q3 2025, Treasury Shares rose 350.94% year-over-year to $5.2 million; the TTM value through Sep 2025 reached $5.2 million, up 350.94%, while the annual FY2024 figure was $5.7 million, 54.04% down from the prior year.
  • Treasury Shares reached $5.2 million in Q3 2025 per ADMA's latest filing, down from $5.5 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $12.5 million in Q4 2023 to a low of $686133.0 in Q2 2021.
  • Average Treasury Shares over 5 years is $5.0 million, with a median of $4.8 million recorded in 2023.
  • Peak YoY movement for Treasury Shares: soared 1289.01% in 2021, then tumbled 76.23% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $4.5 million in 2021, then decreased by 8.8% to $4.1 million in 2022, then soared by 202.77% to $12.5 million in 2023, then crashed by 54.04% to $5.7 million in 2024, then dropped by 9.01% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Treasury Shares are $32.1 million (Q4 2025), $23.2 million (Q3 2025), and $15.1 million (Q2 2025).